Key Development Swiss pharmaceutical major Novartis has formally entered into a definitive agreement to acquire U.S./U.K.-based biotechnology innovator Myricx Bio... Read more
Tag: #M&A
Institutional Capital Hedging via Royalty Consolidation: Analyzing Zymeworks’ $929 Million Takeover of Theravance
Key Development Global oncology therapeutics specialist Zymeworks (Vancouver, Canada) has entered into a definitive merger agreement to acquire the distressed... Read more
The $4 Billion VMS Bidding War: Unilever and Haleon Counter-Bid for L Catterton’s High-Growth Asset, Thorne
Key Development The global consumer health and wellness ecosystem has transformed into a high-stakes corporate battlefield as fast-moving consumer goods... Read more
Late-Stage Asset Crystallization: Analyzing Ipsen’s $1.7 Billion Strategic Acquisition of Kartos Therapeutics
Key Development Global biopharmaceutical leader Ipsen (Euronext: IPN; ADR: IPSEY) has formally entered into a definitive merger agreement to acquire... Read more
Consolidating Oncological Diagnostics: Analyzing Agilent’s $950 Million Acquisition of Biocare Medical
Key Development Global life sciences and diagnostics titan Agilent Technologies Inc. has officially finalized its previously announced acquisition of Biocare... Read more
Realigning the Life Sciences Architecture: Analyzing Merck KGaA’s $11.3 Billion Bio-Techne Takeover
Key Development German healthcare and electronics conglomerate Merck KGaA has finalized a definitive, blockbuster agreement to acquire Bio-Techne Corporation in... Read more
Industrial Adhesives Pivot to MedTech: Analyzing H.B. Fuller’s $942 Million Acquisition of Advanced Medical Solutions
Key Development U.S.-based industrial adhesives manufacturer H.B. Fuller has finalized a definitive agreement to acquire Advanced Medical Solutions Group (AMS),... Read more
AbbVie closes in on a definitive $11 billion corporate buyout of biotech Apogee Therapeutics
Global pharmaceutical giant AbbVie is nearing a definitive agreement to acquire Apogee Therapeutics—an advanced developer of targeted inflammatory disease therapies—in... Read more
Sun Pharma acquires Innovcare Lifesciences in a Rs 271.2 crore all-cash transaction
Sun Pharmaceutical Industries Ltd, India's largest drugmaker, has signed a definitive agreement to acquire 100% of the outstanding shares of... Read more









